SPARC touches the roof on getting US FDA approval for Epilepsy Drug Keppra XR Generic

11 Sep 2013 Evaluate

Sun Pharma Advanced Research Company (SPARC) is currently trading at its upper circuit limit of Rs. 131.90, up by 11.95 points or 9.96 % from its previous closing of Rs. 119.95 on the BSE.

The scrip opened at Rs. 120.00 and has touched a high and low of Rs. 131.90 and Rs. 120.00 respectively. So far 273933 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 174.00 on 29-May-2013 and a 52 week low of Rs. 73.55 on 11-Sep-2012.

Last one week high and low of the scrip stood at Rs. 131.90 and Rs. 118.50 respectively. The current market cap of the company is Rs. 3122.13 crore.

The promoters holding in the company stood at 67.13 % while Institutions and Non-Institutions held 7.71 % and 25.16 % respectively. Sun Pharma Advanced Research Company (SPARC) has received US FDA (Food and Drug Administration) approval for Epilepsy Drug Keppra XR Generic. Keppra is an anti-epileptic drug used to treat partial onset seizures in people with epilepsy. Keppra is also used to treat tonic-clonic seizures in adults and children who are at least 6 years old, and myoclonic seizures in adults and children who are at least 12 years old. Keppra may also be used for purposes not listed in this medication guide.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

133.25 -0.50 (-0.37%)
30-Dec-2025 09:58 View Price Chart
Peers
Company Name CMP
Syngene Internation. 649.35
Indegene 519.50
CMS Info Systems 340.25
Sagility 52.20
Smartworks Coworking 464.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×